MRG006A treatment for advanced solid tumors

A Phase I/II, Open-label, Multi-center, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of MRG006A in Patients With Advanced Solid Tumors

This will test whether the antibody–drug conjugate MRG006A is safe and can help adults with advanced solid tumors.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 343 (estimated)
• Ages: 17 Years to 85 Years
• Sex: All
• Sponsor: Lepu Biopharma Co., Ltd. (Industry-sponsored)
• Locations: 2 sites (Beijing, Beijing Municipality and 1 other locations)
• Trial ID: NCT07093970 on ClinicalTrials.gov

What this trial studies

This two-part phase 1/2 interventional study tests MRG006A, an antibody–drug conjugate, in adults with advanced solid tumors. Phase 1 uses dose escalation to determine the maximum tolerated dose and recommended phase 2 dose while monitoring safety, pharmacokinetics, and immunogenicity. Phase 2 is a dose-expansion cohort at the confirmed dose to further measure tumor response by RECIST v1.1 (and mRECIST for HCC), safety, PK, and immunogenicity. Eligible patients must have measurable disease, ECOG 0–1, adequate organ function, and in some cases provide tumor tissue for GPC3 and P53 testing.

Who should consider this trial

Good fit: Adults 18–75 years old with histologically or cytologically confirmed advanced solid tumors, at least one measurable lesion, ECOG performance status 0–1, and adequate organ function are the intended candidates.

Not a fit: Patients with severe liver failure, symptomatic large thoracoabdominal or pericardial effusions, poor performance status, or who are pregnant or breastfeeding are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, MRG006A could shrink or slow growth of some advanced solid tumors and provide a new targeted treatment option.

How similar studies have performed: Antibody–drug conjugates have delivered notable benefits in several cancers, but MRG006A itself is a novel agent that has not yet been proven in patients.

Eligibility criteria

Inclusion Criteria:

1. Understand and provide written informed consent and comply with the requirements set forth in the protocol.
2. age ≥ 18 years, ≤ 75 years.
3. Expected survival ≥ 3 months.
4. For patients with stage I and II disease, tumor tissue samples for GPC3 and P53 testing must be provided.
5. Patients with histologically or cytologically confirmed advanced solid tumors.
6. At least one measurable lesion according to RECISTv1.1 and mRECIST (HCC patients).
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
8. Organ function must meet basic requirements.
9. Women who are pregnant or breastfeeding are not included in this study.
10. Female and male patients of childbearing potential must agree to take adequate measures.

Exclusion Criteria:

1. Moderate and above thoracoabdominal pelvic fluid and pericardial effusion with clinical symptoms.
2. History of liver failure and hepatic encephalopathy.
3. Portal vein tumor thrombus involving both the main portal vein and left and right branches, or involving both the main portal vein and mesenteric vein needs to be excluded. The tumor involves the vena cava, or has formed a vena cava tumor thrombus.
4. Residual toxicity due to previous anti-tumor therapy or clinically significant laboratory abnormalities higher than grade 1 (CTCAEv5.0).
5. For liver cancer, previous or current central nervous system metastases and/or meningeal metastases. Patients with treated stable brain metastases from non-hepatic cancers may participate.
6. Patients at high risk of bleeding.
7. Severe cardiac insufficiency within 6 months prior to enrollment.
8. Pulmonary embolism or deep venous thrombosis within 3 months before the first study drug treatment;
9. History of gastrointestinal perforation, fistula, and bowel obstruction, extensive bowel resection, Crohn 's disease, ulcerative colitis, or chronic diarrhea for the past 6 months.
10. Patients with double cancer and multiple cancer.
11. Uncontrolled or poorly controlled disease.
12. History of ventricular tachycardia or torsades de pointes.
13. Previous or combined interstitial pneumonia, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm and other medical history;
14. Allergic reactions to any component or excipient of MRG006A, or known Grade ≥ 3 allergic reactions to other prior anti-GPC3 or other monoclonal antibodies.
15. Acute or chronic active hepatitis B or C infection.
16. Active or clinically poorly controlled serious infection.
17. Receiving anti-tuberculosis treatment or receiving anti-tuberculosis treatment within 1 year before the first dose.
18. People infected with human immunodeficiency virus (HIV), known syphilis infection requiring treatment.
19. Use of systemic corticosteroids within 4 weeks prior to first treatment.
20. Use of strong CYP3A4 inducers, strong CYP3A4 inhibitors within 14 days or 5 times the half-life prior to the first dose.

Where this trial is running

Beijing, Beijing Municipality and 1 other locations

• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China (Recruiting)
• Zhongshan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Principal investigator: Jian Zhou, M.D. — Fudan University
• Study coordinator: Program Director

Conditions Advanced Solid Tumors; MRG006A; Antibody Drug Conjugate